Purpose: To determine the severity and duration of the loss of eyelid sensation after upper eyelid crease incision.
Methods: This clinic-based case study was performed by analyzing observational measurements of patients undergoing upper blepharoplasty or ptosis surgery. Eighty-three eyelids of 50 patients were studied. A Cochet-Bonnet filament-type aesthesiometer was used to obtain all measurements. Preoperative and postoperative measurements were recorded at 1 week, 1 month, and final (2-6 months) time periods. Statistical analysis evaluated the degree and duration of the sensory loss and the extent of recovery during the evaluation period. Recovery of sensation was defined as a numerical reading within one point of baseline.
Results: The mean aesthesiometry reading was calculated at the preoperative (3.45), 1-week (1.20), 1-month (1.56), and final postoperative (2.56) periods. Paired t testing showed a decreased but significant difference in sensation measurement at each comparison. Recovery of sensation to within one point occurs at the preoperative to late time period comparison. All but 4 of the 68 eyelids tested at the 1-week postoperative time period had a measured loss of sensation. Of the 44 eyelids tested at the final time period, all but 1 had regained some or all of this sensory loss.
Conclusions: Loss of skin sensation in the eyelid after upper eyelid crease incision blepharoplasty or blepharoptosis repair occurs in most patients and should be considered an expected outcome of the procedure. Partial to complete recovery of eyelid sensation over 2 to 6 months should also be expected, though in rare instances this does not occur.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00002341-200201000-00007 | DOI Listing |
Indian Dermatol Online J
October 2024
Department of Dermatology, S. Nijalingappa Medical College, Bagalkot, Karnataka, India.
Background: Dermatophytosis is widespread in India due to recalcitrant and resistant infection. Tinea incognito (TI) is modified dermatophytosis due to the inadvertent use of topical steroids (TS). Similarly, topical steroid-damaged face (TSDF) is caused by prolonged use of TS.
View Article and Find Full Text PDFCureus
November 2024
Plastic Surgery, Excel Hospital, New Delhi, IND.
Background Transconjunctival blepharoplasty using the postseptal technique provides direct access to orbital fat, offering reduced risk of complications, such as ectropion, entropion, fat over-resection, and inferior oblique muscle palsy. This study aims to evaluate the clinical outcomes and safety of transconjunctival blepharoplasty using the postseptal technique, focusing on the incidence of postoperative complications, the recovery time, and the feasibility of combining ancillary procedures with this approach. Methods In this retrospective observational study, we analyzed the outcomes of 88 patients who underwent transconjunctival postseptal blepharoplasty at a private hospital in northern India between July 2022 and January 2024.
View Article and Find Full Text PDFJ Vis Exp
November 2024
Department of Molecular Physiology & Biophysics, University of Iowa; Department of Psychiatry, University of Iowa;
Spontaneous pain has been challenging to track in real time and quantify in a way that prevents human bias. This is especially true for metrics of head pain, as in disorders such as migraine. Eye squint has emerged as a continuous variable metric that can be measured over time and is effective for predicting pain states in such assays.
View Article and Find Full Text PDFCureus
October 2024
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, JPN.
, the oriental eyeworm, is a zoonotic parasite that primarily infects the eyes, causing symptoms such as foreign body sensation, tearing, and itching. It is transmitted by fruit flies like and commonly affects dogs and cats. This case report describes an 18-year-old woman who presented with complaints of "a worm in her left eye.
View Article and Find Full Text PDFAm J Case Rep
October 2024
Northwell Health, New Hyde Park, NY, USA.
BACKGROUND Trastuzumab (Herceptin) is a recombinant DNA-derived humanized monoclonal antibody that the US Food and Drug Administration (FDA) approved in 1998 for metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer therapy. It selectively binds to the extracellular domain of HER2 and mediates an antibody-dependent cellular toxicity in various tissues. Trastuzumab use alone does not typically cause aggressive ocular complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!